Barclays Initiates Coverage on Astrana Health (NASDAQ:ASTH)

Barclays began coverage on shares of Astrana Health (NASDAQ:ASTH) in a report issued on Tuesday, MarketBeat reports. The firm set an “equal weight” rating and a $36.00 price target on the stock. Barclays‘s target price suggests a potential upside of 19.92% from the stock’s current price.

ASTH has been the topic of a number of other research reports. Robert W. Baird decreased their target price on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. Truist Financial lowered their price objective on Astrana Health from $50.00 to $46.00 and set a “buy” rating on the stock in a research note on Tuesday, March 18th. Bank of America cut their price objective on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Stifel Nicolaus decreased their target price on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, February 20th. Finally, Macquarie raised shares of Astrana Health to a “hold” rating in a report on Monday, December 16th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $53.29.

Astrana Health Trading Up 0.5 %

ASTH stock opened at $30.02 on Tuesday. Astrana Health has a one year low of $23.12 and a one year high of $63.20. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of 23.09, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. The company has a fifty day moving average price of $33.47 and a two-hundred day moving average price of $41.49. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. Equities analysts anticipate that Astrana Health will post 1.15 EPS for the current year.

Hedge Funds Weigh In On Astrana Health

A number of institutional investors have recently added to or reduced their stakes in the stock. Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Astrana Health during the fourth quarter worth $40,000. Quarry LP increased its holdings in Astrana Health by 35.5% in the 4th quarter. Quarry LP now owns 1,799 shares of the company’s stock worth $57,000 after purchasing an additional 471 shares in the last quarter. KBC Group NV raised its position in Astrana Health by 108.4% in the fourth quarter. KBC Group NV now owns 2,530 shares of the company’s stock valued at $80,000 after purchasing an additional 1,316 shares during the last quarter. US Bancorp DE raised its position in Astrana Health by 3,880.0% in the fourth quarter. US Bancorp DE now owns 4,776 shares of the company’s stock valued at $151,000 after purchasing an additional 4,656 shares during the last quarter. Finally, PharVision Advisers LLC acquired a new stake in shares of Astrana Health during the fourth quarter valued at about $211,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.